Renalytix Plc (AIM: RENX)

Market Cap	31.46M
Revenue (ttm)	1.75M
Net Income (ttm)	-20.91M
Shares Out	331.21M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,794
Open	9.15
Previous Close	9.50
Day's Range	9.15 - 10.00
52-Week Range	6.50 - 74.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 18, 2025

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa...

• Industry: Medical - Healthcare Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 102
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: RENX

Financial Performance

In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.

Financial numbers in USD